

Serum chromium does not predict glucose tolerance in late pregnancy^{1,2}

Jenny E Gunton, Graham Hams, Rosemary Hitchman, and Aidan McElduff

ABSTRACT

Background: Chromium is an essential element in human nutrition. Serum concentrations of chromium are not well characterized during pregnancy or in gestational diabetes mellitus.

Objective: The objective of this study was to determine whether low plasma chromium concentrations (≤ 3 nmol/L) are associated with altered glucose, insulin, or lipid concentrations during pregnancy.

Design: The study was conducted prospectively and took place at the medical obstetric clinic of a tertiary referral hospital. Seventy-nine women with abnormal results of a 50-g glucose challenge test in the third trimester of pregnancy were studied. All women had a formal 75-g oral-glucose-tolerance test, and fasting insulin, lipid, and chromium concentrations were determined. Chromium was measured by graphite furnace atomic absorption spectrometry.

Results: The median chromium concentration was 2 nmol/L (95% CI: 0, 12). There were no significant differences in age, plasma glucose, insulin, lipids, calculated insulin resistance, or calculated β cell function between women with normal and those with abnormal (≤ 3 nmol/L) chromium concentrations.

Conclusions: Plasma chromium during pregnancy does not correlate with glucose intolerance, insulin resistance, or serum lipids. Plasma chromium concentrations may not accurately reflect tissue stores of chromium. Several trials showed a beneficial effect of chromium supplementation on glucose tolerance, insulin, and lipids. A method for assessing body chromium stores is required to allow further study. *Am J Clin Nutr* 2001;73:99–104.

KEY WORDS Chromium, glucose intolerance, gestational diabetes, pregnancy, triacylglycerol, cholesterol

INTRODUCTION

Chromium is considered an essential element for humans. A diet lacking in chromium may result in the development of diabetes mellitus. This phenomenon was first described in patients receiving long-term total parenteral nutrition before the routine addition of chromium (1, 2). Diabetes in these patients was resolved with supplemental chromium therapy (1–3).

Chromium is believed to be an insulin-sensitizing agent and may facilitate insulin attachment to the insulin receptor (4). Chromium may improve insulin sensitivity by activating insulin receptor tyrosine kinase, an effect that has been shown in rats

(5), and by inhibiting phosphotyrosine phosphatase (PTP-1), which is a rat homologue of human tyrosine phosphatase (PTP-1B), which inactivates the activated (phosphorylated) insulin receptor. Thus, chromium may promote phosphorylation of, and hence activation of, the insulin receptor, leading to improvement in insulin sensitivity (5).

The dietary requirement for chromium is somewhat controversial. The recommended daily intake in the United States is 0.05–0.2 μg (6). The safe reference dose quoted by the US Environmental Protection Agency is 70000 $\mu\text{g}/\text{d}$ for lifetime exposure (7). It is estimated that 10 million Americans take supplemental chromium, making chromium the second largest-selling mineral supplement after calcium (8).

There are difficulties in the measurement of chromium concentrations. Chromium is a common substance in the general environment and is present in concentrations equal to or greater than those seen in the circulation. This renders contamination a significant problem because the amount of chromium in a sample may increase by much more than the original amount present (6, 9). Contamination is also relevant to studies of hair samples, which are exposed to shampoo, colorants, and the environment. Concentrations of > 3 nmol/L in serum and plasma are considered normal (6, 10, 11). Chromium can be measured in urine, but such measurements similarly do not appear to reflect total body chromium status. It is not known whether chromium status in humans can be assessed by measurement of chromium in other bodily fluids or tissues.

We routinely perform oral-glucose-tolerance tests in all women who have abnormal results of 50-g glucose challenge tests during pregnancy (12). Chromium was measured in these women on the morning of the oral-glucose-tolerance test to determine whether serum chromium had any relation to fasting plasma glucose, insulin, cholesterol, or triacylglycerols or to insulin resistance or β cell function derived from the glucose and insulin measurements using the homeostasis assessment model (13). Our hypothesis was that low plasma concentrations of

¹From the Department of Endocrinology and Pacific Laboratory Medicine Services, Royal North Shore Hospital, St Leonards, Australia.

²Address reprint requests to JE Gunton, Department of Endocrinology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. E-mail: jennyeg@hotmail.com.

Received January 18, 2000.

Accepted for publication June 20, 2000.

TABLE 1
Patient characteristics for the group as a whole and subdivided by serum chromium concentration

	All patients (n = 79)	Patients with chromium ≤3 nmol/L (n = 63)	Patients with chromium >3 nmol/L (n = 16)
Age (y)	32 ± 5 ¹	32 ± 4	32 ± 5
Height (cm)	163 ± 6	164 ± 7	162 ± 7
Prepregnancy weight (kg)	58 (44, 98) ²	60 (34, 130)	56 (45, 79)
Prepregnancy BMI (kg/m ²)	21.9 (16.2, 37.1)	22.0 (14.7, 46.6)	21.5 (18.1, 33.0)
Parity	0.7 (0–3) ³	0.6 (0–3)	0.8 (0–3)
Pregnancy interval (mo)	14	15	14
Race (white/Asian/Arabic)	50/20/8	41/17/5	10/3/3
Time of gestation (wk)	29 (21, 35)	29 (25, 34)	29 (28, 35)

¹ $\bar{x} \pm 1$ SD.

²Median (95% CI).

³Median; range in parentheses.

chromium might be associated with insulin resistance and possibly with hyperglycemia or hypertriglyceridemia, or both.

SUBJECTS AND METHODS

Seventy-nine consecutive women with abnormal results of 50-g glucose challenge tests in the third trimester of pregnancy (1-h plasma glucose concentration, ≥ 7.8 mmol/L) were studied. All women subsequently had a 75-g oral-glucose-tolerance test, interpreted by the guidelines of the Australasian Diabetes in Pregnancy Society (14); a fasting plasma glucose concentration ≥ 5.5 or a 2-h value ≥ 8.0 mmol/L is considered abnormal. The mean (± 1 SD) age of the women was 32 ± 5 y.

At the time of the oral-glucose-tolerance test, all women had fasting insulin, total cholesterol, triacylglycerol, and chromium concentrations measured. No additional venipuncture was performed in these women and there were no deviations from usual care.

Plasma glucose was measured by the hexokinase method. Insulin was measured by radioimmunoassay (Phadaseph AB, Uppsala, Sweden). Total cholesterol was measured by enzyme colorimetric testing (Boehringer Mannheim Systems, Mannheim, Germany). Triacylglycerols were measured by enzyme colorimetric testing (Boehringer Mannheim Systems).

All chromium samples were collected by one investigator (RH). A butterfly set was used and the adaptor was removed after collection of other fasting blood samples. The blood was then allowed to drip into the specially prepared chromium collection tubes. Chromium was measured by graphite furnace atomic absorption spectrometry with a Varian SpectrAA800 Zeeman effect instrument from Varian Australia P/L, Melbourne.

The sample was diluted 3-fold before analysis with a surfactant solution. A 20- μ L aliquot of the diluted sample was atomized from the wall of a graphite furnace in the instrument's workhead by ramped heating to 2700°C. The atomic absorption of ground state chromium atoms was measured at the 357.9-nm line. Nonatomic background absorption at the line was simultaneously measured and subtracted. Solution concentrations were calculated from the maximum atomic signal observed during the atomization pulse relative to a set of matrix-matched calibrators spanning the concentration range (0–96 nmol/L).

Incorporating retained quality-assurance samples in each analysis controlled the determination. The within-run precision at 6 nmol/L was 15% and the between-run precision at 22

nmol/L was 23%. The laboratory performing the determination participates in the quality-assurance program for chromium in serum conducted by Quality Control Technologies (Charlestown, Australia). No alternative techniques for measurement of serum chromium were available.

With use of the homeostasis model (13), insulin resistance was calculated with the formula $\text{insulin}/(22.5e^{-\ln^{\text{glucose}}})$. β Cell function was calculated with use of the formula $20 \times \text{insulin}/(\text{fasting glucose} - 3.5)$.

Means ± 1 SD are presented. Values that were not normally distributed are presented as medians with 95% CIs and were compared by using nonparametric Mann-Whitney rank-sum analysis. Statistics were performed with use of SPSS (version 6; SPSS Inc, Chicago). Our sample size gave a power of $\approx 95\%$ with an α of 5% to detect a difference of 0.75 SD in fasting glucose, 2-h glucose, insulin, cholesterol, or triacylglycerol (15) between groups with normal compared with abnormal chromium measurements. The procedures were in accord with the Helsinki Declaration of 1975, revised in 1983.

RESULTS

The mean age of the participants was 32 ± 4 y. The median body mass index (in kg/m²) calculated from prepregnancy weight was 21.9 (95% CI: 16.2, 37.1). The median gestation at testing was 29 wk (95% CI: 25, 31). When women with chromium concentrations ≤ 3 nmol/L (6, 10, 11) were compared with women with concentrations > 3 nmol/L, there were no significant differences in patient characteristics (Tables 1 and 2).

Twenty-five (31.6%) women had gestational diabetes according to the criteria of the Australasian Diabetes in Pregnancy Society; of these, 7 had elevated fasting concentrations. Fifty-four (68.4%) had normal glucose tolerance; 34.8% of women with low chromium concentrations had gestational diabetes and 27.3% of the women with normal chromium concentrations had gestational diabetes. The median chromium concentrations did not differ significantly between women with normal and those with abnormal glucose tolerance.

There were no significant differences in any test results between the groups with normal and abnormal serum chromium concentrations. There was a trend toward lower triacylglycerol concentrations in women with normal chromium concentrations (2.0 ± 0.6 compared with 2.3 ± 0.8 mmol/L; $P = 0.09$).

Given that there is some controversy about the normal serum chromium concentration (4, 6, 10, 11), we examined the data to

TABLE 2
Variables in the group as a whole and subdivided by serum chromium concentration

	All patients (n = 79)	Patients with chromium ≤3 nmol/L (n = 63)	Patients with chromium >3 nmol/L (n = 16)
50-g challenge (mmol/L)	8.8 ± 1.0 ¹	8.8 ± 1.1	8.6 ± 0.8
Fasting glucose (mmol/L)	4.7 ± 0.6	4.7 ± 0.6	4.8 ± 0.4
2-h glucose (mmol/L)	7.2 ± 1.8	7.4 ± 1.9	6.8 ± 1.2
Insulin (pmol/L)	9.2 (2.9, 30.3) ²	9.2 (2.9, 34.6)	9.7 (2.0, 16.0)
Total cholesterol (mmol/L)	6.7 ± 1.1	6.7 ± 1.2	6.7 ± 0.9
Triacylglycerol (mmol/L)	2.2 ± 0.7	2.3 ± 0.7	2.0 ± 0.6
Chromium (nmol/L)	2 (0, 10)	1 (0, 3)	5 (4, 11)
Gestational diabetes	25 (31.6)	22 (34.9)	3 (18.8)
Insulin resistance	1.9 (0.5, 7.4)	1.9 (0.6, 7.6)	1.9 (0.4, 6.0)
β Cell function	166 (59, 1068)	166 (74, 3461)	165 (31, 591)

¹ $\bar{x} \pm 1$ SD. There were no significant differences between groups.²Median (95% CI).

determine whether there was any cutoff chromium concentration that appeared to be related to differences in lipids or glucose tolerance. We tested serum chromium concentrations of 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 nmol/L but identified no cutoff value at which any significant differences appeared. There were no significant associations when chromium was tested as a continuous variable (**Table 3**).

Body mass index correlated with fasting blood glucose ($P = 0.002$), fasting insulin ($P < 0.001$), calculated β cell function ($P = 0.02$), and insulin resistance ($P < 0.001$). The fasting blood glucose correlated with 2-h glucose ($P < 0.001$), insulin ($P < 0.001$), and triacylglycerols ($P = 0.01$). Fasting insulin also correlated with triacylglycerols ($P = 0.007$). Finally, and importantly, there were no significant correlations between serum chromium concentration and any of the other measures studied.

DISCUSSION

The results of some studies suggested that pregnancy may be associated with chromium depletion (16, 17). These studies used only hair chromium concentrations, and the problems with measurement mentioned in the Introduction of this article may apply to these data. One study examined hair chromium in women with gestational diabetes compared with women with normal glucose tolerance in pregnancy (18) and found lower hair chromium at the end of pregnancy in women with gestational

diabetes. The low median serum concentrations in the present study were consistent with other data that showed lower chromium in pregnancy. A literature search did not locate any studies of serum chromium measurement in pregnancy. Studies of chromium supplementation are summarized in **Table 4**.

A randomized study of 24 women with gestational diabetes who received chromium picolinate supplements ($4 \mu\text{g} \cdot \text{kg} \cdot \text{d}^{-1}$) or placebo found significantly lower fasting glucose and insulin concentrations in the women receiving chromium at 8 wk. Peak glucose and insulin concentrations after a 100-g oral-glucose-tolerance test were also significantly lower (53). A case report of a patient with type 1 diabetes who was receiving chromium picolinate supplementation noted a marked improvement in glycemic control (glycated hemoglobin, 11.3–7.9%) over 3 mo (51). One study in which placebo was compared with 200 μg chromium picolinate/d in 48 patients with type 1 diabetes and in 114 patients with type 2 diabetes showed that ≈70% of patients receiving chromium reduced their oral hypoglycemic medications or insulin doses (48).

A randomized placebo-controlled study of 180 individuals with type 2 diabetes compared placebo, supplementation with 200 μg Cr/d, and supplementation with 1000 μg Cr/d (50). Glycated hemoglobin values improved significantly in both groups receiving supplemental chromium at 4 mo (by 1.0% and 1.9%, respectively). Total cholesterol also decreased significantly at 4 mo in the high-dose group. Other studies showed improvement in lipids with chromium therapy, particularly triacylglycerols (47, 54).

TABLE 3
Correlation coefficients (*r*) of the variables for 79 patients

	BMI	Fasting blood glucose	2-h blood glucose	Insulin	β Cell function	Insulin resistance	Total cholesterol	Triacylglycerols
Chromium	-0.051	-0.005	-0.082	-0.176	-0.107	-0.159	-0.007	-0.152
BMI		0.361 ¹	0.140	0.463 ²	0.285 ³	0.514 ²	-0.012	0.230
Fasting blood glucose			0.449 ²	0.456 ²	-0.304 ¹	0.639 ²	-0.266 ³	0.305 ¹
2-h blood glucose				0.091	-0.141	0.202	-0.17	0.194
Insulin					0.1	0.970 ¹	-0.202	0.305 ¹
β Cell function						0.021	0.05	-0.017
Insulin resistance							-0.277 ³	0.298 ¹
Total cholesterol								0.232 ³

¹ $P < 0.01$.² $P < 0.001$.³ $P < 0.05$.

TABLE 4
Summary of studies of chromium supplementation¹

Diabetes mellitus status	Reference	No. of subjects	Form of supplementation and dosage <i>μg/d</i>	Duration	Significant effects
No	Hopkins et al (19)	12	CrCl ₃ , 250	1 d	↑ GT
No	Levine et al (20)	10	CrCl ₃ , 150	12–16 wk	↑ GT
No	Carter et al (21)	9	CrCl ₃ , 250	1–4 d	None
No	Gurson et al (22)	15	CrCl ₃ , 50	1–6 wk	↑ GT
No	Riales and Albrink (23)	14	CrCl ₃ , 200	12 wk	↑ HDL chol
No	Anderson et al (10)	76	CrCl ₃ , 200	12 wk	Variable
No	Offenbacher and Pi-Sunyer (6)	8	CrCl ₃ , 300	10 wk	None
No	Potter et al (24)	5	CrCl ₃ , 200	5 wk	↑ BCF
No	Martinez et al (25)	85	CrCl ₃ , 200	10 wk	↑ GT
No	Bourn et al (26)	47	CrCl ₃ , 200	10 wk	↑ HDL
No	Urberg and Zimmel (27)	16	CrCl ₃ , 200, niacin	4 wk	↑ GT
No	Urberg et al (28)	2	CrCl ₃ , 200, niacin	52 wk	↓ chol
No	Wang et al (29)	10	CrCl ₃ , 50	12 wk	↓ chol, ↓ LDL
No	Press et al (30)	28	Cr pic, 200	6 wk	↓ chol, ↓ LDL
No	Lefavi et al (31)	34	Cr nic 2–800	8 wk	↓ chol
No	Anderson et al (32)	17	CrCl ₃ , 200	8 wk	↑ GT
No	Roebach et al (33)	63	BA Cr, 600	8 wk	↑ HDL
Yes	Roebach et al (33)	63	BA Cr, 600	8 wk	↑ HDL
Yes	Glinksman and Mertz (34)	6	CrCl ₃ , 180–1000	<20 wk	↑ GT in 3 of 6
No	Glinksman and Mertz (34)	10	CrCl ₃ , 180–1000	1–50 wk	None
No	Offenbacher and Pi-Sunyer (35)	8	Yeast Cr, 11	8 wk	↑ GT, ↓ chol
Yes	Offenbacher and Pi-Sunyer (35)	8	Yeast Cr, 11	8 wk	↑ GT, ↓ ins
No	Abraham et al (36)	51	CrCl ₃ , 250	28–64 wk	↑ HDL, ↓ TG
Yes	Abraham et al (36)	25	CrCl ₃ , 250	28–64 wk	↑ HDL, ↓ TG
No	Uusitupa et al (37)	26	Yeast Cr, 160	24 wk	None
Yes	Uusitupa et al (38)	10	CrCl ₃ , 200	6 wk	↓ ins (60 min)
No	Wilson and Gandy (39)	26	Cr pic, 220	14 wk	↓ ins
No	Thomas and Gropper (40)	14	Cr nic, 200	14 wk	None
Yes	Sherman et al (41)	7	CrCl ₃ , 50	16 wk	None
Yes	Nath et al (42)	12	Reduced Cr, 500	8 wk	↑ GT, ↓ ins, ↓ chol
Yes	Rabinowitz et al (43)	43	CrCl ₃ , 150	16 wk	None
Yes	Mossop (44)	26	CrCl ₃ , 600	16–32 wk	↓ fasting glucose
Yes	Elias et al (45)	6	Yeast Cr, 21	2 wk	↓ fasting glucose
Yes	Evans (46)	11	Cr pic, 200	6 wk	↓ Hb A _{1c} , ↓ LDL
Yes	Lee and Reasner (47)	28	Cr pic, 200	8 wk	↓ TG
Yes	Ravina (48)	162	Cr pic, 200	10 d	↓ glucose, ↓ ins
Yes	Thomas and Gropper (49)	5	Cr nic, 200	8 wk	None
Yes	Anderson et al (50)	185	Cr pic, 200–1000	16 wk	↓ Hb A _{1c} , ↓ chol
Yes	Fox and Sabovic (51)	1	Cr pic, 600	1 wk	↓ Hb A _{1c}
Yes	Jeejeebhoy et al (1)	1	CrCl ₃ , 200	1 wk	Reversal of diabetes
Yes	Freund et al (2)	1	CrCl ₃ , 100	1 wk	Reversal of diabetes
Yes	Brown et al (3)	1	CrCl ₃ , 200	1 wk	Reversal of diabetes
Gestational	Jovanovic-Peterson et al (52)	8	Cr pic, 1–600	3–10 wk	↓ glucose

¹GT, glucose tolerance; chol, cholesterol; BCF, β cell function; pic, picolinate; nic, nicotinate; BA, biologically active; ins, insulin; Hb A_{1c}, glycated hemoglobin; TG, triacylglycerol.

A 1985 review (55) identified 23 studies of chromium supplementation in subjects without diabetes. Of these, 18 studies showed improvement in lipid, glucose, or insulin concentrations ($n = 504$). These studies are summarized in Table 4. Five studies showed no effect of chromium in subjects without diabetes. These studies were small, with a total of 67 patients in all the studies combined. None of the negative studies used chromium picolinate. Picolinate is a stereoisomer of nicotinic acid.

The review also identified 16 studies of chromium supplementation in patients with type 2 diabetes, which are also shown in Table 4. Of these studies, 13 showed a significant improve-

ment in glucose, insulin, or lipid concentrations. These studies included a total of 502 patients. There were 3 studies, with a total of 55 subjects, in which no effect was found.

The form of chromium supplementation, as well as its dose, may be important. The studies with negative results (5 in subjects without diabetes and 3 in subjects with diabetes) used CrCl₃ (5 studies), chromium nicotinate (2 studies), or yeast chromium (1 study). These studies did not use chromium picolinate. The generally small size of these studies in both diabetic and nondiabetic subjects implies a lower power to detect a true difference. In only one of the supplementation studies was serum chromium




measured; modern techniques were used and care was taken to avoid contamination before and after therapy. That study did not find a correlation between change in serum chromium and improvement in glucose tolerance.

Picolinate is an isomeric form of nicotinic acid. Tissue concentrations of chromium have been studied in rats (56). Chromium absorption was studied for chromium chloride, chromium potassium sulfate, chromium picolinate, and other forms of chromium. Hepatic chromium incorporation was most pronounced with chromium picolinate. None of the studies with any of the forms of chromium showed harmful effects of chromium supplementation.

Few data are available regarding tissue concentrations of chromium, and adequate concentrations of tissue chromium are not known. The results of a study using intravenously administered $^{51}\text{Cr}^{3+}$ suggest that there is a plasma pool of chromium in relatively rapid equilibrium with tissue compartments (34). The plasma pool was very small ($\approx 0.13 \mu\text{g}$) and the turnover time was 5–12 min. Chromium accumulation in muscle, adipose tissue, and liver were shown, with much slower turnover, and larger pools, of up to 190 times the plasma pool ($25 \mu\text{g}$). Thus, chromium in serum may not accurately reflect total body stores, and body stores may be relevant to the effects on insulin action.

This study confirmed, with careful collection and sample preparation, that plasma chromium concentrations are lower than those reported in many previous studies but similar to those of other investigators who used careful collection methods and technique. The measurement of chromium in serum did not correlate with measurements of insulin resistance, glucose tolerance, or lipids in pregnant women, even though the study was appropriately powered. This study did not indicate whether tissue concentrations of chromium are related to these measures.

Further studies are needed, including 1) investigation of tissue concentrations of chromium and 2) further studies of chromium supplementation, which should incorporate measurements of serum chromium to ascertain whether baseline chromium or changes in serum chromium are predictive of a therapeutic effect. 

REFERENCES

- Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg R, Bruce-Robertson AS. Chromium deficiency, glucose intolerance and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition. *Am J Clin Nutr* 1977;30:531–8.
- Freund H, Ataman S, Fischer JE. Chromium deficiency during total parenteral nutrition. *JAMA* 1979;241:496–8.
- Brown RO, Forloines-Lynn S, Cross RE, Heifer WD. Chromium deficiency after long-term total parenteral nutrition. *Dig Dis Sci* 1986;31:661–4.
- Mertz W, Toepfer EW, Roginski EE, Polansky MM. Present knowledge of the role of chromium. *Fed Proc* 1974;33:2275–80.
- Davis CM, Sumall KH, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. *Biochemistry* 1997;36:4381–5.
- Offenbacher EG, Pi-Sunyer PX. Chromium in human nutrition. *Annu Rev Nutr* 1988;8:543–63.
- Mertz W, Abernathy CO, Olin SS. Risk assessment of essential elements. Washington, DC: ILSI Press, 1994:19–38.
- Hellerstein MK. Is chromium supplementation effective in managing type II diabetes? *Nutr Rev* 1998;56:302–6.
- Offenbacher EG, Spencer H, Dowling J, Pi-Sunyer FX. Metabolic chromium balances in men. *Am J Clin Nutr* 1986;44:77–82.
- Anderson RA, Bryden NA, Polansky MM. Serum chromium of human subjects: effects of chromium supplementation and glucose. *Am J Clin Nutr* 1985;41:571–7.
- Veillon C. Trace element analysis of biological samples. *Anal Chem* 1986;58:851A–8A.
- Hitchman R, Mathur G, McElduff A. Screening for gestational diabetes. What is the no-show rate? *Diabetes Care* 1998;21:674–5 (letter).
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412–9.
- Hoffman L, Nolan C, Wilson JD, Oats JN, Simmons D. Gestational diabetes mellitus—management guidelines. The Australasian Diabetes in Pregnancy Society. *Med J Aust* 1998;169:93–7.
- Bach LA, Sharpe K. Sample size for clinical and biological research. *Aust N Z J Med* 1989;19:64–8.
- Hambridge KM, Rodgerson DO. Comparison of hair chromium levels of nulliparous and parous women. *Am J Obstet Gynecol* 1969;103:320–1.
- Mahalko JR, Bennion M. The effect of parity and time between pregnancies on maternal hair chromium concentration. *Am J Clin Nutr* 1976;29:1069–72.
- Aharoni A, Tesler B, Paltieli Y, Dori Z, Sharf M. Hair chromium content of women with gestational diabetes compared with non-diabetic pregnant women. *Am J Clin Nutr* 1992;55:104–7.
- Hopkins LL Jr, Ransome-Kuti O, Majaj AS. Improvement of impaired carbohydrate metabolism by chromium (III) in malnourished infants. *Am J Clin Nutr* 1968;21:203–11.
- Levine RA, Streeten DHP, Doisy RJ. Effects of oral chromium supplementation on the glucose tolerance of elderly subjects. *Metabolism* 1968;17:114–25.
- Carter JP, Kattab A, Abd-El-Hadi K, Davies JT, el Gholmy AK, Patwardhan VN. Chromium (III) in hypoglycemia and impaired glucose utilization in kwashiorkor. *Am J Clin Nutr* 1968;21:195–202.
- Gurson CT, Saner G. Effect of chromium on glucose utilization in marasmic protein-calorie malnutrition. *Am J Clin Nutr* 1971;24:1313–9.
- Riales R, Albrink MJ. Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high density lipoprotein of adult men. *Am J Clin Nutr* 1981;34:2670–8.
- Potter JF, Levin P, Anderson RA, Frieberg JM, Andres R, Elahi D. Glucose metabolism in glucose-intolerant older people during chromium supplementation. *Metabolism* 1985;34:199–204.
- Martinez OB, MacDonald AC, Gibson RS, Bourn O. Dietary chromium and effect of chromium supplementation on glucose tolerance of elderly Canadian women. *Nutr Res* 1985;5:609–20.
- Bourn DM, Gibson RS, Martinez OB, MacDonald AC. The effect of chromium supplementation on serum lipids in a selected sample of Canadian postmenopausal women. *Biol Trace Elem Res* 1986;9:197–205.
- Urberg M, Zempel MB. Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans. *Metabolism* 1987;36:896–9.
- Urberg M, Benyi J, John R. Hypocholesterolemic effects of nicotinic acid and chromium supplementation. *J Fam Pract* 1988;27:603–6.
- Wang MM, Fox EA, Stoeker BJ, Menendez CE, Chan SB. Serum cholesterol of adults supplemented with brewer's yeast or chromium chloride. *Nutr Res* 1989;9:989–98.
- Press RI, Geller J, Evans GW. The effect of chromium picolinate on cholesterol and apolipoprotein fractions in human subjects. *West J Med* 1990;152:41–5.
- Lefavi RG, Wilson GD, Keith RE, et al. Lipid lowering effect of dietary chromium (III)-nicotinic acid complex in male athletes. *Nutr Res* 1993;13:239–49.
- Anderson RA, Polansky MM, Bryden NA, Canary J. Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. *Am J Clin Nutr* 1991;54:909–16.

33. Roebach JR Jr, Mae K, Chambless LE, Fletcher RH. Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers. *Ann Intern Med* 1991; 115:917–24.
34. Glinsmann WH, Mertz W. Effect of trivalent chromium on glucose tolerance. *Metabolism* 1966;15:510–20.
35. Offenbacher KG, Pi-Sunyer X. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. *Diabetes* 1980;29:919–25.
36. Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. *Metabolism* 1992;41:768–71.
37. Uusitupa MIJ, Kumpulainen JT, Voutilainen E, et al. Effect of inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in noninsulin-dependent diabetics. *Am J Clin Nutr* 1983;38:404–10.
38. Uusitupa MIJ, Mykkanen L, Siitonen O, et al. Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels. *Br J Nutr* 1992;68:209–16.
39. Wilson BE, Gondy A. Effect of chromium supplementation on fasting insulin levels and lipid parameters in healthy, non-obese young subjects. *Diabetes Res Clin Pract* 1995;28:179–94.
40. Thomas VLK, Gropper SS. Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors. *Biol Trace Elem Res* 1997;55:297–305.
41. Sherman L, Glennon JA, Brech WJ, Klomberg GH, Gordon ES. Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus. *Metabolism* 1968;17:439–42.
42. Nath R, Minocha J, Lyall V, et al. Assessment of chromium metabolism in maturity onset and juvenile diabetes using chromium 51 and therapeutic response of chromium administration on plasma lipids, glucose tolerance and insulin levels. In: Shapcott D, Hubert J, eds. *Chromium in nutrition and metabolism*. Amsterdam: Elsevier/North Holland, 1979:213–22.
43. Rabinowitz MB, Gonick HC, Levine SR, Davidson MB. Clinical trial of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. *Biol Trace Elem Res* 1983;4:449–66.
44. Mossop RT. Effects of chromium (III) on fasting glucose, cholesterol and cholesterol HDL levels in diabetics. *Cent Afr J Med* 1983;29:80–2.
45. Elias AN, Grossman MK, Valenta LJ. Use of the artificial beta cell (ABC) in the assessment of peripheral insulin sensitivity; effect of chromium supplementation in diabetic patients. *Gen Pharmacol* 1984;15:535–9.
46. Evans GW. The effect of chromium picolinate on insulin controlled parameters in humans. *Int J Biosoc Med Res* 1989;11: 163–80.
47. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. *Diabetes Care* 1994;17:1449–52.
48. Ravina A, Slezak L, Rubal A, Mirsky N. Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. *J Trace Elem Exp Med* 1995;8:183–90.
49. Thomas VLK, Gropper SS. Effect of chromium nicotinic acid supplementation on selected cardiovascular risk factors. *Biol Trace Elem Res* 1997;55:297–305.
50. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. *Diabetes* 1997;46:1786–91.
51. Fox GN, Sabovic Z. Chromium picolinate supplementation for diabetes mellitus. *J Fam Pract* 1998;46:83–6.
52. Jovanovic-Peterson L, Gutierrez M, Peterson CM. Chromium supplementation for gestational diabetic women (GDM) improves glucose tolerance and decreases hyperinsulinemia. *Diabetes* 1996; 43:337a.
53. Jovanovic-Peterson L, Peterson CM. Vitamin and mineral deficiencies which may predispose to glucose intolerance of pregnancy. *J Am Coll Nutr* 1996;15:14–20.
54. Anderson RA. Chromium, glucose intolerance and diabetes. *J Am Coll Nutr* 1998;17:548–55.
55. Lim TH, Sargent T, Kusubov N. Kinetics of trace element chromium (III) in the human body. *Am J Physiol* 1983;244:R445–54.
56. Anderson RA, Bryden NA, Polansky MM, Gautschi K. Dietary chromium effects on tissue chromium absorption in rats. *J Trace Elem Exp Med* 1996;9:11–25.

